Sponsors:
This activity is jointly sponsored by Postgraduate Institute for Medicine and IMPACt, Inc.
Contact Postgraduate Institute for Medicine
Commercial Support:
This activity is supported by an educational grant from Eli Lilly and Company.
Description:
"Virtual Lung Tumor Board" is a case-based discussion highlighting current issues and changing dynamics in the treatment of NSCLC. The panel of experts will discuss the most appropriate management options for the cases and emphasize a multidisciplinary team approach to treatment.
Learning Objectives:
Upon completion of this activity, participants will be able to:
- Select appropriate surgical, radiological and systemic treatment strategies for patients at different stages of disease.
- Outline the growing data on how NSCLC tumor characteristics (clinical and molecular) may point towards individualizing therapy
- Identify the role of adjuvant therapy in earlier stage NSCLC
- Describe the treatment of unresectable, locally advanced NSCLC and the controversial role of consolidation therapy
- Explain the treatment of metastatic disease (Stage IV) including 2nd and 3rd line therapy
- Cite recent clinical trial results exploring the use of targeted agents in NSCLC
Target Audience:
This activity has been designed to meet the educational needs of medical, radiation and surgical oncologists involved in the care of patients with lung cancer.
Accreditation Statement:
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Postgraduate Institute for Medicine (PIM) and IMPACt, Inc. PIM is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation:
Postgraduate Institute for Medicine designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Faculty:
Corey J. Langer, MD (Course Director)
Professor, Department of Medicine
Director of the Thoracic Oncology Program
University of Pennsylvania
Walter J. Curran Jr., MD, FACR
Lawrence W. Davis Professor and Chair
Department of Radiation Oncology
Chief Medical Officer, Winship Cancer Institute
Steven M. Keller, MD
Chief, Division of Thoracic Surgery
Professor of Cardiothoracic Surgery
Albert Einstein College of Medicine
Disclosure of Conflicts of Interest:
Postgraduate Institute for Medicine (PIM) assesses conflict of interest with its instructors, planners, managers and other individuals who are in a position to control the content of CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by PIM for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Corey J. Langer, MD
Consulting fees: Bristol-Myers Squibb, Eli Lilly and Company, Genentech, Imclone, OSI, sanofi-aventis, US
Speakers’ Bureau: Bristol-Myers Squibb, Eli Lilly and Company, Genentech, Imclone, OSI, sanofi-aventis,
Walter J. Curran, Jr., MD, FACR
Consulting fees: AstraZeneca, Bristol-Myers Squibb, Genentech, Imclone, Pfizer
Stock ownership: ITA Partners
Steven M. Keller, MD
No significant financial relationship with any commercial entity related to this activity
The following PIM and IMPACt, Inc. clinical content reviewers, Linda Graham, RN; Jan Hixon, RN, Jan Schultz, RN, BSN, MSN, Trace Hutchison, PharmD and Scott McMahon hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interests related to the content of this CME activity or any amount during the past 12 months.
Disclaimer:
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.